ISFTD 2026 - Initial Biomarker Results from a Phase 2a Clinical Trial of Neflamapimod in Patients with nfvPPA (8ac11b)

Cervomed Inc. published this content on October 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 26, 2026 at 08:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]